RESULTS OF MONITORING OF PRESCRIPTION OF POTENTIALLY DANGEROUS COMBINATIONS OF DRUGS IN PHARMACOTHERAPY UNDER INPATIENT TREATMENT

Overview & Synopsis

In case of combined pharmacotherapy, between drugs can occur interactions, which can be dangerous to the life and health of patients. Such combinations of drugs are considered to be one of the serious clinical problems, and are considered as errors that can be prevented. Therefore, it is relevant to determine the frequency of such appointments for further work on their prevention. Aim of the research. Determine the structure and prevalence of the appointments of potentially dangerous combinations of drugs in the treatment of patients under inpatient treatment for further optimization of pharmacotherapy. Materials and methods. In the automated mode, the lists of medical appointments of patients who were under inpatient treatment of 30 health facilities of Zhytomyr region in 2017 were monitored for the purpose of the simultaneous use of drugs, the interaction of which is dangerous. For further analysis by the levels of clinical significance using the Drug Interaction Checker system, the "Major" (hazardous) and "Moderate" (significant) combinations were selected on the Internet resource www.drugs.com. The frequency of the appointments of dangerous combinations, their prevalence by the nosological classes and the profiles of the offices of medical institutions was determined. Results. As a result of the monitoring of 69405 cases, it was found that the average number of prescriptions per patient was 5.6±1.2 titles. In 1390 cases of treatment (2.0 % of 69405) simultaneously prescribed medicines, the interaction of which could be dangerous. In the structure of dangerous combinations, 81.5 % is taken with the simultaneous administration of drugs containing active substances ketorolac and pentoxifylline. The frequency of potentially dangerous appointments was greatest in the treatment of patients with diseases of the blood and blood-forming organs (D50-D89) – 11.6 %, in diseases of the musculoskeletal system and connective tissue (M00-M99) – 7.7 %, in diseases of the nervous system – 5.0 % of all cases of treatment.